US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US6306426B1
(en)
*
|
1997-08-11 |
2001-10-23 |
Allergan Sales, Inc. |
Implant device with a retinoid for improved biocompatibility
|
CA2300154C
(en)
*
|
1997-08-11 |
2008-07-08 |
Allergan Sales, Inc. |
Sterile bioerodible implant device with improved biocompatability and method
|
CA2358296A1
(en)
*
|
1999-01-05 |
2000-07-13 |
Anthony P. Adamis |
Targeted transscleral controlled release drug delivery to the retina and choroid
|
WO2001028473A1
(en)
|
1999-10-21 |
2001-04-26 |
Alcon Universal Ltd. |
Sub-tenon drug delivery
|
US6416777B1
(en)
|
1999-10-21 |
2002-07-09 |
Alcon Universal Ltd. |
Ophthalmic drug delivery device
|
US7943162B2
(en)
|
1999-10-21 |
2011-05-17 |
Alcon, Inc. |
Drug delivery device
|
PT1473003E
(pt)
|
1999-10-21 |
2008-12-26 |
Alcon Inc |
Dispositivo para administração de fármacos
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
DK1313415T3
(da)
|
2000-08-30 |
2008-10-13 |
Univ Johns Hopkins |
Indretninger til intraokulær lægemiddeladministration
|
DE60114229T2
(de)
|
2000-11-29 |
2006-07-06 |
Allergan, Inc., Irvine |
Verhinderung von transplantatabstossung im auge
|
AU2002319596B2
(en)
|
2001-07-23 |
2006-04-27 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
CN100349562C
(zh)
|
2001-07-23 |
2007-11-21 |
爱尔康公司 |
眼部药物输送装置
|
FI118172B
(fi)
|
2002-04-22 |
2007-08-15 |
Inion Ltd |
Kirurginen implantti
|
AU2003217531A1
(en)
*
|
2002-05-02 |
2003-11-17 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
EP1521573B1
(de)
*
|
2002-07-15 |
2008-01-02 |
Alcon, Inc. |
Nichtpolymere lipophile pharmazeutische implantat-zusammensetzungen für die intraokulare anwendung
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
WO2004073551A2
(en)
*
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
US8404269B2
(en)
*
|
2003-04-11 |
2013-03-26 |
Michael Snyder |
Sustained release implantable eye device
|
JP4824549B2
(ja)
*
|
2003-05-02 |
2011-11-30 |
サーモディクス,インコーポレイティド |
制御放出型の生体活性物質デリバリー・デバイス
|
US8246974B2
(en)
|
2003-05-02 |
2012-08-21 |
Surmodics, Inc. |
Medical devices and methods for producing the same
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
KR20060082792A
(ko)
*
|
2003-07-10 |
2006-07-19 |
알콘, 인코퍼레이티드 |
안과용 약물 전달 장치
|
US7585517B2
(en)
*
|
2003-09-18 |
2009-09-08 |
Macusight, Inc. |
Transscleral delivery
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
CA2549161A1
(en)
*
|
2003-12-02 |
2005-06-23 |
Allergan, Inc. |
Prevention and/or reduction of photoreceptor degeneration with retinoids
|
WO2005072701A1
(en)
|
2004-01-20 |
2005-08-11 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
WO2005110374A1
(en)
*
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
AU2005240078A1
(en)
*
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
WO2006002366A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Surmodics, Inc. |
Biodegradable ocular devices, methods and systems
|
JP2008505978A
(ja)
*
|
2004-07-12 |
2008-02-28 |
アラーガン、インコーポレイテッド |
眼病用組成物および眼病治療法
|
WO2006023130A2
(en)
*
|
2004-08-12 |
2006-03-02 |
Surmodics, Inc. |
Biodegradable controlled release bioactive agent delivery device
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
BRPI0607606B1
(pt)
*
|
2005-02-09 |
2021-06-22 |
Santen Pharmaceutical, Co., Ltd. |
Formulação líquida
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
US8003124B2
(en)
*
|
2005-04-08 |
2011-08-23 |
Surmodics, Inc. |
Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
|
US7931909B2
(en)
*
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
AU2006261342B2
(en)
|
2005-06-15 |
2012-02-02 |
The Ohio State University Research Foundation |
Her-2 peptides
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
EP1926504B1
(de)
*
|
2005-09-21 |
2010-01-13 |
SurModics, Inc. |
In situ okklusionszusammensetzungen mit natürlichen biologisch abbaubaren polysacchariden
|
JP5745208B2
(ja)
*
|
2005-10-18 |
2015-07-08 |
アラーガン インコーポレイテッドAllergan,Incorporated |
後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
|
SI1968594T1
(sl)
|
2005-11-29 |
2011-01-31 |
Glaxosmithkline Llc |
Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
EP1993584B1
(de)
|
2006-02-02 |
2012-05-30 |
Allergan, Inc. |
CXCR4-Hemmer-Therapie zur Verwendung bei der Behandlung von Augenerkrankungen
|
EP2001438A2
(de)
|
2006-02-09 |
2008-12-17 |
Macusight, Inc. |
Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
|
JP5506378B2
(ja)
|
2006-03-23 |
2014-05-28 |
参天製薬株式会社 |
血管透過性に関連する疾患または病気のための製剤および方法
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
US7946296B2
(en)
*
|
2006-05-26 |
2011-05-24 |
Philip Morris Usa Inc. |
Dissolvable tobacco film strips and method of making the same
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20080020014A1
(en)
*
|
2006-07-19 |
2008-01-24 |
Paul Consigny |
Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
|
US20080097335A1
(en)
*
|
2006-08-04 |
2008-04-24 |
Allergan, Inc. |
Ocular implant delivery assemblies
|
TW200831497A
(en)
*
|
2006-10-12 |
2008-08-01 |
Epix Delaware Inc |
Carboxamide compounds and their use
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8586556B2
(en)
*
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
WO2008070479A2
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US20080147021A1
(en)
*
|
2006-12-15 |
2008-06-19 |
Jani Dharmendra M |
Drug delivery devices
|
US8846073B2
(en)
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
US20080265343A1
(en)
*
|
2007-04-26 |
2008-10-30 |
International Business Machines Corporation |
Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
|
US8231892B2
(en)
*
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
US8003621B2
(en)
|
2007-09-14 |
2011-08-23 |
Nitto Denko Corporation |
Drug carriers
|
JP2011506466A
(ja)
|
2007-12-11 |
2011-03-03 |
株式会社サイトパスファインダー |
カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US8202531B2
(en)
*
|
2008-07-23 |
2012-06-19 |
Warsaw Orthopedic, Inc. |
Drug depots having one or more anchoring members
|
CN101386203B
(zh)
*
|
2008-10-15 |
2011-09-14 |
广州卫视博生物科技有限公司 |
折叠式人工玻璃体制造方法及其模具
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
US8034813B2
(en)
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US8632511B2
(en)
|
2009-05-06 |
2014-01-21 |
Alcon Research, Ltd. |
Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
|
IN2012DN00352A
(de)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
CN102724951A
(zh)
|
2009-11-09 |
2012-10-10 |
阿勒根公司 |
用于刺激毛发生长的组合物和方法
|
US8177747B2
(en)
|
2009-12-22 |
2012-05-15 |
Alcon Research, Ltd. |
Method and apparatus for drug delivery
|
EP2720539B1
(de)
|
2011-06-14 |
2018-10-24 |
Bikam Pharmaceuticals, Inc. |
Opsinbindende liganden, deren zusammensetzungen und anwendungsverfahren
|
US8772273B2
(en)
|
2011-10-04 |
2014-07-08 |
Quretino Therapeutics, Inc. |
Formulations and uses of retinoic acid receptor selective agonists
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2944628B1
(de)
|
2011-11-30 |
2017-01-04 |
Bikam Pharmaceuticals, Inc. |
Opsinbindende liganden, zusammensetzungen und verfahren zur verwendung
|
EP2785178B1
(de)
|
2011-12-01 |
2019-05-01 |
Bikam Pharmaceuticals, Inc. |
Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
|
US9308355B2
(en)
|
2012-06-01 |
2016-04-12 |
Surmodies, Inc. |
Apparatus and methods for coating medical devices
|
US9827401B2
(en)
|
2012-06-01 |
2017-11-28 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US11090468B2
(en)
|
2012-10-25 |
2021-08-17 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
KR20150119254A
(ko)
|
2013-02-15 |
2015-10-23 |
알러간, 인코포레이티드 |
지속된 약물 전달 임플란트
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
AU2018369784B2
(en)
|
2017-11-14 |
2023-06-01 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
WO2020112816A1
(en)
|
2018-11-29 |
2020-06-04 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US11819590B2
(en)
|
2019-05-13 |
2023-11-21 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
CN111861124B
(zh)
*
|
2020-06-18 |
2023-07-25 |
汕头大学 |
适用于注塑机的可识别性能评估方法、系统及存储介质
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|